We conducted a prospective study in a cohort of HR+/HER2- mBC patients to assess the concordance of ESR1 mutation evaluated on matched tumor tissue samples from a metastatic lesion and ctDNA from plasma. This evidence concerns the gene ERBB2 and neoplasm.